Search results
Results From The WOW.Com Content Network
Website. www.medimmune.com [dead link] MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. [1][2] MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. [3]
Durvalumab, [8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. [9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1 (CD279).
Mavrilimumab is a human monoclonal antibody [1] that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). [2] Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc. [1] as an investigational drug for the treatment of rheumatoid arthritis.
C6504H10080N1732O2044S44. Molar mass. 146 652.90 g·mol −1. Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. [8][9][5] Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. [5]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5][7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. [medical citation needed] Anifrolumab was approved for medical use in the United ...
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. [1] It targets interferon a. [2] Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials. [3][4][5]
Website. www.sap.com /products /human-resources-hcm.html. SAP SuccessFactors is an American multinational company headquartered in South San Francisco, California, providing cloud-based software for human capital management using the Software as a service (SaaS) model. Competitors include Workday, Oracle Cloud HCM, ADP, and Ceridian.